AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04993417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mime Therapy along with EMS
Description: All the subjects carried out the treatment process for a total of 3 months. During this treatment duration, the sessions were administered 3 times per week for 45 minutes, depending upon the subject's ability to focus and tiredness. Mime treatment incorporates self kneading of face and neck, breathing and relaxation works out, activities to synchronize the two sides and diminish synkinesis and for eye and lip closure per the myofascial way to deal with recovery, letter and word practices and expressive activities.
Study NCT01446003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8457
Description: 10 x 10-mg capsule BID for 10 days
Study NCT04194606 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Use of radial artery for access for a coronary angiography or intervention
Description: After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
Study NCT04194606 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Use of radial artery for access for a coronary angiography or intervention
Description: After puncture of the radial artery in either the area of the anatomical snuffbox or the lower forearm following modified Seldinger technique a sheath will be advanced and a CAG or PCI will be performed. After the procedure is finished the sheath will be withdrawn and a standard closure device will be applied to achieve hemostasis. The choice of the patients side, the sheath, the catheters and the closing device will be at the discretion of the interventionalist.
Study NCT02036749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nerve block
Description: quadratus lumborum block
Study NCT02036749 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: nerve block
Description: quadratus lumborum block
Study NCT00640393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etanercept
Description: Etanercept 50 mg, subcutaneous (SC) injection.
Study NCT00640393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nbUVB
Study NCT02098486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study NCT04323215 — intervention group
Intervention type: DEVICE
Intervention: Support system
Description: A support system named Provement will be used to provide behavioral treatment.
Study NCT02098486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Study NCT05318443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIBP04
Description: SIBP04, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
Study NCT05318443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Avastin, 15mg/kg, intravenous infusion, the first intravenous infusion 90min (+10min), 3 weeks/cycle, administered on the first day of each treatment cycle.
Study NCT05318443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
Study NCT05318443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel, 175mg/m2, intravenous infusion, every 3 weeks/cycle, administered on the first day of each treatment cycle.
Study NCT05318443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
Study NCT01446003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for MK-8457
Description: 10 x 10-mg capsule BID for 10 days
Study NCT05318443 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC=5.0, (upper limit 800mg), intravenous infusion, 3 weeks/cycle, administered on the first day of each treatment cycle.
Study NCT00332566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPw-HBV/Hib Kft vaccine GSK323527A
Description: Intramuscular injection, 1 dose
Study NCT00332566 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix™-HepB/Hiberix™
Description: Intramuscular injection, 1 dose
Study NCT02632916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months
Study NCT03715829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Induction dose 1. Oral tablet taken QD
Study NCT02632916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months
Study NCT02684084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex
Description: OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
Study NCT02684084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
Study NCT01095718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Errorless Learning
Description: Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.~The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.~The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.~During cueing the patient will mostly receive verbal and visual cues and if necessary physical help.
Study NCT01095718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modeling
Description: The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps.
Study NCT01095718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trial and Error
Description: The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.~The therapist does the steps, at the same time he/she uses verbal cues during the performance.~Then the therapist asks immediately to the patient to do the steps.
Study NCT02165423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: myFAMI iPad application
Study NCT02621788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training for Residents (SMART-R)
Description: The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
Study NCT01423357 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condom distribution and peer education
Description: Condom distribution and condom demonstrations by youth peer educators at least twice a week
Study NCT00430677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids (prednisone or prednisolone)
Description: tablets, oral, 0.5-0.8 mg/kg, daily
Study NCT00430677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: intravenous solution, injectable, 30 mg/kg, every 28 days
Study NCT00430677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: intravenous solution, injectable, 10 mg/kg, every 28 days
Study NCT00430677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: tablets, oral, 1.5 to 2 g, daily
Study NCT01796353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sexual rehabilitation
Description: exercise plus psycho-education
Study NCT01796353 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: usual care
Study NCT03035409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin Hydrochloride
Description: Given PO
Study NCT03466320 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKR-2
Description: This Phase I study will explore the hypothesis that the administration of modified T-cells targeting NKG2D-ligands expressed by AML/MDS cells, after a prior nonmyeloablative preconditioning treatment, in patients refractory to and/or relapsing after prior therapies, is safe and, considering the poor outcomes and lack of therapeutic strategies for this patient population, may have a strategic advantage over current approaches and provide potential clinical benefit.
Study NCT03035409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Undergo physical activity
Study NCT03035409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03035409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional Assessment
Description: Undergo nutritional counseling
Study NCT03035409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03035409 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00907868 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: partial breast irradiation
Description: Patients undergo radiation tumor bed boost
Study NCT00907868 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole breast irradiation
Description: Patients undergo whole breast irradiation
Study NCT00907868 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Description: Patients undergo whole breast irradiation
Study NCT01456260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
Study NCT01456260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
Study NCT01456260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Description: TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
Study NCT01456260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
Study NCT01456260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
Study NCT01456260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
Study NCT01691612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: installation of D. pteronyssinus allergens
Description: We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
Study NCT01257646 — intervention group
Intervention type: OTHER
Intervention: Gait analysis
Description: A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
Study NCT01532973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir
Description: Elbasvir was administered orally by tablet(s)
Study NCT01532973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched placebo tablets were administered orally.
Study NCT01879605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docusate natrium and sorbitol
Study NCT01879605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Study NCT02096393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zimmer Patient specific instruments
Description: A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
Study NCT02096393 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard instrumentation
Description: Standard instrumentation will be used during total knee replacement surgery.
Study NCT02745210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 13C magnetic resonance spectroscopy
Description: acquisition of 13C MR spectroscopy in the brain
Study NCT02312271 — intervention group
Intervention type: OTHER
Intervention: enteral formula
Description: standard tube feeding formulas
Study NCT00003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00434850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Pancreatic Islet Cells
Description: Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
Study NCT00434850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxyspergualin
Description: An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
Study NCT00434850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antithymocyte globulin
Description: Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
Study NCT00434850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daclizumab or basiliximab
Description: Will replace antithymocyte globulin in all islet transplantations after the first one
Study NCT03715829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Induction dose 2. Oral tablet taken QD
Study NCT03715829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: Maintenance dose A. Oral tablet taken QD
Study NCT00003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT00003350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00003350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT00434850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Maintenance immunosuppressive therapy
Study NCT00434850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Maintenance immunosuppressive therapy
Study NCT00434850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Blocks TNF-alpha which is toxic to islet cells
Study NCT01757704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open pleurae & conventional filling of heart
Description: After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
Study NCT01757704 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intact pleurae & staged filling of heart
Description: After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
Study NCT04212793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab-IRDye800CW
Description: Intravenous administration of 4.5, 10 or 25 mg of Bevacizumab-IRDye800CW prior to endoscopic transsphenoidal surgery
Study NCT04212793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Molecular Fluorescence Endoscopy platform
Description: A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working channel of the Surgvision explorer endoscope. During surgery, three imaging moments are defined in which the fluorescence molecular endoscopy system will detect the fluorescent signal
Study NCT04040712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donor FMT
Description: Fecal microbiota transplantation using stools from healthy donors
Study NCT04040712 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham FMT
Description: Sham fecal microbiota transplantation
Study NCT02890199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine liposomal
Study NCT02750943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride
Description: Dentifrice containing 0.454% w/w stannous fluoride
Study NCT02750943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Monofluorophosphate
Description: Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
Study NCT00814788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg oral tablet daily
Study NCT00814788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg oral capsule daily
Study NCT01467583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: 2.5 mg every 48 hours
Study NCT03177291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).~Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation.
Study NCT03177291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
Study NCT03177291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 200 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
Study NCT03177291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
Study NCT03306927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whole yellow pea chili
Description: Chili containing whole yellow peas
Study NCT03306927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Split yellow pea chili
Description: Chili containing split yellow peas
Study NCT03306927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice chili
Description: Chili containing long grain white rice
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Participants will receive active tDCS at up to 4mA per electrode for up to 40 minutes for up to 260 sessions.
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: Participants will receive sham tDCS for up to 260 sessions
Study NCT03036319 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham tDCS
Description: Participants will receive sham tDCS for up to 260 sessions